Overview

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a dose-seeking and efficacy study of combined BRAF Inhibitor Vemurafenib and High-dose Interferon alfa-2b for therapy of advanced melanoma.
Phase:
Phase 1
Details
Lead Sponsor:
John Kirkwood
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Interferon alpha-2
Interferon-alpha
Interferons
Vemurafenib